Cargando…
Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma
Several factors have been found to be predictors of a good response following omalizumab treatment in patients with severe allergic asthma (SAA). However, it remains unclear whether clinical characteristics can predict a minimal clinically important difference (MCID) following omalizumab treatment i...
Autores principales: | Huang, Wei-Chang, Fu, Pin-Kuei, Chan, Ming-Cheng, Chin, Chun-Shih, Huang, Wen-Nan, Lai, Kuo-Lung, Wang, Jiun-Long, Hung, Wei-Ting, Wu, Yi-Da, Hsieh, Chia-Wei, Wu, Ming-Feng, Chen, Yi-Hsing, Hsu, Jeng-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761618/ https://www.ncbi.nlm.nih.gov/pubmed/35047521 http://dx.doi.org/10.3389/fmed.2021.762318 |
Ejemplares similares
-
The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment
por: Huang, Wei-Chang, et al.
Publicado: (2021) -
Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016) -
Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)